Normunity

New Haven, United States

Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.

$75.0M raised

Jan 2025

Series B

Top Investors

HSGCanaan PartnersSamsara BioCapitalConnecticut InnovationsOUP (Osage University Partners)

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Normunity raised?

Normunity has raised $75.0M in total funding. The most recent round was Series B. The last funding was announced in January 2025.

Who are Normunity's investors?

Normunity's investors include HSG, Canaan Partners, Samsara BioCapital, Connecticut Innovations, OUP (Osage University Partners).

Where is Normunity headquartered?

Normunity is headquartered in New Haven, United States.

What does Normunity do?

Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.

What stage is Normunity at?

Normunity is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 13, 2025.

MLA

"Normunity — Funding & Investors." VCBacked, January 13, 2025, https://www.vcbacked.co/company/normunity. Accessed June 4, 2026.

APA

VCBacked. (2025). Normunity — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/normunity

Wikipedia (cite web)

{{cite web |title=Normunity — Funding & Investors |url=https://www.vcbacked.co/company/normunity |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 13, 2025.